Prescribing information

 

Prescribing information

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Discover a variety of on-demand webinars providing information on multiple sclerosis and KESIMPTA.

If you would like to express interest in future events, please use the ‘Contact’ button, and a Novartis representative will be in touch.

Video preview ‘Developing a Kesimpta (ofatumumab) patient pathway for your MS service protocol’. Video discusses ‘the treating of MS patients outside of the hospital setting’.

Developing a KESIMPTA patient pathway for your MS service protocol

Watch Dr David Paling and Ms Joela Mathews discuss the treatment of MS patients outside of the hospital setting.

Watch

Podcast of KESIMPTA Launch event

KESIMPTA Launch event

Watch and hear MS experts answer questions, and discuss key themes and topics on RRMS and KESIMPTA.

Access

 

Video preview ‘KESIMPTA regional launch meetings’.

KESIMPTA Regional launch meetings

Watch MS experts in your area introduce KESIMPTA’s mode of action, dosing and administration, and clinical efficacy and safety.

Watch

Video preview for At the limits Multiple sclerosis series

At the limits Multiple sclerosis series

Watch MS experts present the pivotal data for KESIMPTA in MS, take us through the immunology involved, and discuss real-life patient case studies.

Watch

 

MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.

Rate this content: 
No votes yet
UK | February 2022 | 187892
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]